Home
overview

SUPERBUGS & SUPERDRUGS 2017

2 DAY CONFERENCE: 20TH & 21ST MARCH
2 INTERACTIVE WORKSHOPS: 22ND MARCH (For details visit the ASSOCIATED EVENTS tab)


SMi is proud to present the 2017 19th annual Superbugs & Superdrugs conference, taking place on 20th and 21st March in Central London.
Expanding horizons on the growing threat of anti-microbial resistance for almost two decades, the flagship show in the global Superbugs portfolio of events will once again play host to an international audience of scientific leaders, funding bodies and drug discovery specialists, providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities.

Each year, around 2 million people are taken ill in the US from antibiotic-resistant bacteria and kills at least 23,000, according to estimates by the Centers for Disease Control and Prevention. The threat is so high that in September 2014 President Barack Obama issued an executive order Combating Antibiotic-Resistant Bacteria. *

The threat is the same in Europe, big pharmaceutical companies are re-entering the space into development of new antibiotics after decades. In January 2016, more than 80 pharmaceutical, biotechnology and diagnostics companies including Roche, Pfizer, Novartis AG and GlaxoSmithKline pledged at the World Economic Forum to fight the threat of antimicrobial resistance.*

The industry’s premier event on antibiotic resistance will provide a perfect platform for its growing "superbugs" community to network, exchange novel solutions and consolidate current strategies. A must attend for both new and seasoned stakeholders involved in AMR and infectious disease.

https://www.fredhutch.org/en/news/center-news/2015/01/combating-superbugs-superdrugs-antibiotics.html
http://www.iol.co.za/business/international/big-pharma-drawn-back-to-antibiotics-2040209

PREVIOUS ATTENDEE TESTIMONIALS FROM SUPERBUGS & SUPERDRUGS 2016

  • “Great meeting to network and have time to discuss face to face. Key questions and issues. Very collaborative open meeting.” – Roche
  • “It was one of the most useful scientific conferences that I have attended” – BARDA
  • “Good mix of problems such as funding and novel opportunities and success stories” – TNO
  • “I enjoyed attending the meeting this year and wanted to thank you for your efforts in organizing it” – UNT Health Science Centre
  • “I like the mix of early stage technologies and also later stage products being presented” – Sempra Pharmaceuticals

WHAT'S ON THE AGENDA FOR 2017?

• The latest developments in antimicrobial peptides
• Ground-breaking innovations in antibacterial chemotherapy
• Comprehensive overview of government funding initiatives
• A showcase on novel approaches to enabling antibacterial activity against Gram-negative pathogens
• Guidance on antibiotic stewardship
• Updates on clinical progress
• New spotlight on animal models in drug discovery
• Hand on training through CPD certified interactive workshops

CEOs, Chiefs, VPs, Directors, Heads, Principals of:
 

Antibacterial
Infectious Disease
R&D
Microbiology

or working in the area of superbugs and superdrugs from pharmaceutical, biotech and research organizations!
 

7i Med Ltd; ACT Surfaces ; Alacrita LLP; Anti-infectives ; Antikor Biopharma; Arsanis Biosciences GmbH; Auspherix Ltd; BARDA; BIOASTER; Blueberry Therapeutics Ltd. ; Cantab Anti-infectives; Cempra Pharmaceuticals; Centauri Therapeutics; Chemical Biology Ventures; Clarivate Analytics; Da Volterra; Drugs for Neglected Diseases initiative (DNDi); dstl (Defence Science and Technology Laboratory); Elsevier; Emergent BioSolutions; Emergent BioSolutions Inc.; European Commision; Evotec; F. Hoffmann-La Roche; F. Hoffmann-La Roche Ltd.; Fidelta Ltd; GOETZPARTNERS CORPORATE FINANCE LIMITED; Karolinska Institute; KWS BioTest; Laboratoire Biodim; Medecins Sans Frontieres; MGB Biopharma; MHRA; Mutabilis S A; Neem Biotech; Nemesis bioscience ; NeoSome Life Sciences, LLC; Northern Antibiotics Ltd.; Nosopharm; Office of Health Economics (OHE); Phico Therapeutics; Phico Therapeutics Ltd; Polyphor Ltd; QuantumDX; Sankio Pharma Gmbh; Spero Therapeutics; St George's, University of London; The Wellcome Trust; Tiber Creek Partners; TNO Pharma; TranScrip Partners; TranScrip Partners LLP; University Hospital of Copenhagen ; University Of Liverpool; University of North Texas Health Science Center; Venaticus Symcel ; VIB; Wellcome Trust;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Richard Bax

Richard Bax, Senior Partner, TranScrip Partners

9:10 Regulatory perspective on antibacterial drug development

Sumathi Nambiar

Sumathi Nambiar, Director, Division of Anti-Infective, FDA


-Discuss streamlined development programs
-Activities to facilitate antibacterial drug development
-Discuss some remaining challenges in antibacterial drug development    
 

9:50 Repopulating the Antibacterial Pipeline

Christopher Houchens

Christopher Houchens, Branch Chief, Antibacterials Program, BARDA

• What is BARDA?
• Why BARDA is interested in antimicrobial resistance (AMR)
• How BARDA is addressing the issue of AMR
• Forming innovative public-private partnerships to
accelerate clinical product development
• Stimulating innovation in early stage antimicrobial
research and development

10:30 Morning Coffee

10:50 SYN-004 (ribaxamase): A Novel Orally Delivered Therapy Designed to Protect the Gut Microbiome from the Detrimental Effects of Intravenous ß-lactam Antibiotics

Dr Andrew Bristol

Dr Andrew Bristol, Vice President of Development, Synthetic Biologics, Inc.
View Bio

  • Antibiotics cause disruption of the gut microbiome, which can lead to C.diff infection
  • SYN-004 (ribaxamase) is a b-lactamase enzyme developed to inactivate b-lactam antibiotics excreted into the intestine before reaching the colon
  • Presentation of preclinical study results in pigs demonstrating prevention of dysbiosis by SYN-004, and prevention of emergent antibiotic-resistance genes
  • Presentation of clinical study results, Phase 1 and Phase 2 studies
  • Future plans, including b-lactamase formulation compatible with oral b-lactams, development of carbapenemase (SYN-006)
  • 11:30 Sequence-specific antimicrobials for targeted eradication of carriage

    Xavier Duportet

    Xavier Duportet, CEO, Eligo Bioscience

    -Describe the delivery of programmable DNA circuits into targeted populations of the microbiome
    -How this can be used to precisely sculpt the microbiome
    -Eradicate specific bacterial pathogen while sparing the beneficial microbiota.
     

    12:10 Networking Lunch

    13:10 Innate defense regulators: Agnostic therapy for antibiotic resistant disease

    Oreola Donini

    Oreola Donini, Chief Scientific Officer, Soligenix, Inc.
    View Bio

  • Innate immunity is a complementary approach for treatment of bacterial infectious diseases
  • Preclinical studies demonstrated an ability to combat infection, irrespective of the infectious bacterial pathogen, whether Gram-positive or Gram-negative, intracellular or extracellular, or antibiotic sensitive or resistant while modulation of inflammation and enhanced tissue healing were also observed
  • Clinically, the lead clinical IDR, dusquetide, has been demonstrated to be safe and efficacious in Phase 1 and 2 studies.
  • In a Phase 2 study, dusquetide reduced the duration of severe oral mucositis in head and neck cancer patients receiving chemoradiation therapy, while also decreasing the incidence of bacterial infections.
  • 13:50 EU COMBACTE Consortium: Combatting bacterial resistance in Europe in a public-private partnership

    Ron de Winter

    Ron de Winter, Project leader, UMC Utrecht

  • Part of EU action plan New Drugs for Bad Bugs (ND4BB) against the rising threats from Antimicrobial Resistance
  • improving the efficiency of research and development of new antibiotics
  • open sharing of knowledge between pharma industry and academi
  • addressing the barriers to clinical development of antibiotics
  • innovative trial designs to facilitate the registration of novel antibacterial agents
  • over fifteen international trials, involving both (registration) clinical trials with drugs under development and investigator-initiated research
  • a premier Europe-wide network of hospitals and laboratories prepared for and experienced in performing high-quality clinical studies
  • 14:30 Statistical and design approaches to allow more feasible antibiotic drug development

    Aaron Dane

    Aaron Dane, Director, Danestat consulting

    • A n outline of alternative statistical approaches and study
    designs are being considered and actively discussed
    with global regulatory agencies
    • H ow likely they are to be possible going forward
    • D iscussion of which approaches can already be applied
    and which require further work before being considered
    part of routine practice

    15:10 Afternoon Tea

    15:30 The development of antimicrobial peptides (AMP) as new antibacterial drugs

    Deborah O'Neil

    Deborah O'Neil, Chief Executive Officer, Novabiotics Ltd

    • Exploring AMP as a viable alternative to antibiotics
    • Utilising an AMP different mode of action
    • Latest developments in antimicrobial peptides

    16:10 Short antimicrobial peptides - their potential to treat bacterial MDR infections

    Kai Hilpert

    Kai Hilpert, Prof Associate Reader in Infection and Immunology , St George's, University of London

    • Screening approach and separation of antimicrobial
    activity and haemolytic activity
    • Their action against MDR strains
    • Preventing biofi lms and destroying existing biofi lms
    • Immunomodulatory activities

    16:50 Novel approaches to enabling antibacterial activity against Gram-negative pathogens

    Aileen  Rubio

    Aileen Rubio, Head of Biology, Spero Therapeutics

    • Combating Gram negative pathogens require
    innovative approaches in addition to the standard small
    molecules
    • We have identifi ed an outer membrane permeabilizer,
    SPR741, that helps otherwise impermeant antibiotics
    entry into the Enterobacteriaecaea.
    • Improvements in activity can be observed both in vitro
    and in vivo when SPR741 is combined with rifampin or
    other antibiotics

    17:30 Chairman’s Closing Remarks and Close of Day One

    Richard Bax

    Richard Bax, Senior Partner, TranScrip Partners

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures

    9:10 Antibiotic evaluation: Current challenges and the opportunities

    Nicole  Mahoney

    Nicole Mahoney, Global Regulatory Policy, MSD
    View Bio

    • What’s the relationship between how we study priority antibiotics and their true value to society?
    • Are there new opportunities to assess antibiotic value?                
    • The role industry can play in helping to preserve the value of antibiotics
     

    9:50 How the pharmaceutical industry is helping address AMR?

    James Anderson

    James Anderson, Head of Government Affairs, GSK

    · The role of the pharmaceutical industry in combating AMR goes beyond investing in R&D for new antibiotics
    · Companies are partnering with healthcare systems globally to help ensure antibiotics are manufactured cleanly, available to patients where needed and used appropriately
    · We seek further progress on implementation of new economic models to deliver sustainable solutions for all.
     

    10:30 Morning Coffee

    10:50 The use of in vivo models for infectious disease research

    William Weiss

    William Weiss, Director of Pre-Clinical Services, University of North Texas Health Science Center
    View Bio

    • Experimental Design of Animal Models
    • Bridging the gap – in vitro activity to in vivo effi cacy
    • Where to start / What model to use
    • What does the data tell us

    11:30 Finding new small molecule antibiotics

    David Williams

    David Williams, Chief Executive Officer, Discuva

    • Fast and effi cient ways to fi nd new antibiotic
    chemotypes
    • Ways to focus rational chemical optimisation
    • Selection of the best clinical candidates
    • Management of clinical resistance

    12:10 Networking Lunch

    13:10 Fighting back against MBL mediated CREs: development of metallo-beta-lactamase inhibitors for use in combination with carbapenems

    Martin Everett

    Martin Everett, Chief Scientific Officer, Antabio

    • MBL-mediated CRE are already endemic in many countries
    and rapidly spreading world-wide
    • Antabio have identifi ed a potent and selective lead series
    with excellent drug-like properties
    • Lead compounds show broad spectrum potentiation of
    meropenem against clinical CRE isolates and demonstrate
    effi cacy in animal models of infection

    13:50 Microbome-targeted products: Spare vs repair

    Jean de Gunzburg

    Jean de Gunzburg, CSO, Da Volterra

    • Antibiotic-induced dysbiosis and its consequences
    • FMT and microbiota-derived products aimed at
    C. diffi cile infections
    • Pharmacological interventions targeting the gut
    microbiome
    • Protecting the intestinal microbiome during antibiotic
    treatments

    14:30 Afternoon Tea

    14:50 Exploiting DNA topoisomerases as targets for antibacterial chemotherapy

    Anthony Maxwell

    Anthony Maxwell, Professor, John Innes Centre

    • AMR is a serious and growing problem
    • DNA topoisomerases (e.g. DNA gyrases) are successful
    and well-validated targets for antibiotics
    • Fluoroquinolones are highly-successful antibacterial
    agents, but resistance is a serious problem
    • Approaches to discover new gyrase inhibitors
    • Topoisomerases present new opportunities for antibiotic
    targeting

    15:30 Anti-infective monoclonal antibodies against multi-drug resistant pathogens

    Eszter Nagy

    Eszter Nagy, President and CSO, Arsanis Biosciences GmbH

  • The benefit of mAbs with multiple modes of action and multi-specificity
  • Pre-emptive approach for high-risk patients is highly attractive
  • mAb therapy to increase antibiotic effectiveness with directly anti-bacterial and/or anti-virulence mechanisms
  • 16:10 Discovery of a novel class of antibiotics

    Richard Rutter

    Richard Rutter, Chief Scientific Officer, Auspherix Ltd

    • Identifi cation of a new class of broad-spectrum
    antibacterials
    • Antimicrobial profi les (Gram-positive & Gram-negative)
    • In-vitro characterisation and mechanistic insights

    16:50 Novel oligonucleotide antimicrobials against Gram-negative infections

    Michael McArthur

    Michael McArthur, Chief Scientific Officer, Procarta Biosystems Ltd.

    · Rational design of oligonucleotide antimicrobials to target transcription factors
    · Identification of a new Gram-negative therapeutic target
    · Validation in microbiome and animal models

    17:30 Chairman’s Closing Remarks and Close of Day Two

    Lloyd Czaplewski

    Lloyd Czaplewski, Director, Chemical Biology Ventures

    +

    FEATURED SPEAKERS

    Aileen  Rubio

    Aileen Rubio

    Head of Biology, Spero Therapeutics
    Christopher Houchens

    Christopher Houchens

    Branch Chief, Antibacterials Program, BARDA
    Dr Andrew Bristol

    Dr Andrew Bristol

    Vice President of Development, Synthetic Biologics, Inc.
    Eszter Nagy

    Eszter Nagy

    President and CSO, Arsanis Biosciences GmbH
    Jean de Gunzburg

    Jean de Gunzburg

    CSO, Da Volterra
    Richard Bax

    Richard Bax

    Senior Partner, TranScrip Partners

    Aaron Dane

    Director, Danestat consulting
    Aaron Dane

    Aileen Rubio

    Head of Biology, Spero Therapeutics
    Aileen  Rubio

    Anthony Maxwell

    Professor, John Innes Centre
    Anthony Maxwell

    Christopher Houchens

    Branch Chief, Antibacterials Program, BARDA
    Christopher Houchens

    David Williams

    Chief Executive Officer, Discuva
    David Williams

    Deborah O'Neil

    Chief Executive Officer, Novabiotics Ltd
    Deborah O'Neil

    Dr Andrew Bristol

    Vice President of Development, Synthetic Biologics, Inc.
    Dr Andrew Bristol

    Andrew Bristol, Ph.D., is currently the Vice-President of Development at Synthetic Biologics, Inc. in Rockville, MD. He has more than 20 years experience in biological drug development in research, development and manufacturing. Dr. Bristol is currently interested in elucidating mechanisms of microbial drug resistance and developing active agents to protect the gut microbiome from antibiotic-associated dysbiosis. He has developed multiple biologicals products in various phases of clinical testing - including peptides, viral vectors and recombinant monoclonal antibodies and proteins.

    Eszter Nagy

    President and CSO, Arsanis Biosciences GmbH
    Eszter Nagy

    James Anderson

    Head of Government Affairs, GSK
    James Anderson

    Jean de Gunzburg

    CSO, Da Volterra
    Jean de Gunzburg

    Kai Hilpert

    Prof Associate Reader in Infection and Immunology , St George's, University of London
    Kai Hilpert

    Lloyd Czaplewski

    Director, Chemical Biology Ventures
    Lloyd Czaplewski

    Martin Everett

    Chief Scientific Officer , Antabio
    Martin Everett

    Michael McArthur

    Chief Scientific Officer, Procarta Biosystems Ltd.
    Michael McArthur

    Nicole Mahoney

    Global Regulatory Policy, MSD
    Nicole  Mahoney

    Dr. Nicole Mahoney is Director, Global Regulatory Policy at MSD. Her work is focused on leading MSD’s efforts in guiding U.S. and international regulatory policy on infectious disease therapies. In this capacity, she supports cross-functional teams responsible for the company’s portfolio of investigational and approved antibacterial medicines, providing strategic input on key issues throughout the life-cycle of these products.
    Nicole also represents the company on the Innovative Medicine Initative’s Driving re-investment in R&D and responsible use of antibiotics (DRIVE-AB) project, a joint undertaking by the EU and European Pharmaceutical Industry Association focused on spurring antibiotic innovation and research.
    Prior to joining MSD, Nicole served as the senior officer for the Pew Charitable Trusts' antibiotics and innovation project and as a U.S. Food and Drug Administration Commissioner’s Fellow in the FDA’s Office of Antimicrobial Products, analyzing trends in the regulatory process for all new antibiotics reviewed by the agency over three decades. She earned her PhD in biochemistry from the Albert Einstein College of Medicine and completed postdoctoral training at the University of California, San Francisco.
     

    Oreola Donini

    Chief Scientific Officer, Soligenix, Inc.
    Oreola Donini

    Oreola Donini has more than 15 years experience in drug discovery and preclinical development with start-up biotechnology companies and has been instrumental in leading early stage development of several novel therapies into the clinic. Dr. Donini has worked previously with ESSA Pharma Inc., Inimex Pharmaceuticals Inc. and Kinetek Pharmaceuticals Inc., developing novel therapies for infectious disease, cancer and cancer supportive care. Dr. Donini is a co-inventor and leader of the SGX94 Innate Defense Regulator technology. She was responsible for overseeing the manufacturing and preclinical testing of SGX94, which demonstrated efficacy in combating bacterial infections and mitigating the effects of tissue damage due to trauma, infection, radiation and/or chemotherapy treatment. These preclinical studies culminated in a successful Phase 1 and Phase 2 clinical studies demonstrating efficacy in reducing the duration of severe oral mucositis in head and neck cancer patients (a function of a dysregulated inflammatory innate immune response) and an ability to reduce the rate of infections in these same patients. While with ESSA Pharma as the Vice President of Research and Development, Dr. Donini led the preclinical testing of a novel N-terminal domain inhibitor of the androgen receptor for the treatment of prostate cancer. She has previously worked in immunology and oncology. Dr. Donini received her PhD from Queen’s University in Kinston, Ontario, Canada and completed her post-doctoral work at the University of California, San Francisco. Her research has spanned drug discovery, preclinical development, manufacturing and clinical development in infectious disease, cancer and cancer supportive care.
     

    Richard Bax

    Senior Partner, TranScrip Partners
    Richard Bax

    Richard Rutter

    Chief Scientific Officer, Auspherix Ltd
    Richard Rutter

    Ron de Winter

    Project leader, UMC Utrecht
    Ron de Winter

    Sumathi Nambiar

    Director, Division of Anti-Infective, FDA
    Sumathi Nambiar

    William Weiss

    Director of Pre-Clinical Services, University of North Texas Health Science Center
    William Weiss

    Bill Weiss is currently the Director of Preclinical Services at the University of North Texas Health Science Center in Fort Worth. He uses his 33 years of experience and expertise in infectious disease research to direct the evaluations of antibacterial agents, including established models of both acute and chronic bacterial infections in several different animal species as well as pharmacokinetic studies and HPLC or LCMS analysis in collaboration with large pharmaceutical companies, the biotech industry as well as academia. Prior to this, he was Director of Drug Evaluation at Cumbre Pharmaceuticals Inc. His responsibilities included animal efficacy models, pharmacology and all pre-clinical microbiology research and development efforts focused on the discovery and development of new antimicrobial agents. Previously, he was a Group Leader in Infectious Disease Discovery Research at Wyeth Research, Lederle Laboratories and Schering-Plough and has held various positions of responsibility in antibacterial, antiviral and antifungal discovery research. He has worked on numerous antibacterial programs including the development of the marketed products, Suprax, Zosyn and Tygacil. His expertise encompasses the development and evaluation of animal models of infectious disease as well as pharmacokinetic and pharmacodynamic analysis. He has authored / co-authored over 90 research presentations and journal articles.

    Xavier Duportet

    CEO, Eligo Bioscience
    Xavier Duportet

    Sponsors and Exhibitors

    Official Media Partner

    Official Publication

    Supporters

    Workshops

    The Use of Animal Models in Pre-Clinical Drug Development
    Workshop

    The Use of Animal Models in Pre-Clinical Drug Development

    Holiday Inn London - Kensington
    22nd March 2017
    London, United Kingdom

    Practical Challenges in Developing Novel Antimicrobials
    Workshop

    Practical Challenges in Developing Novel Antimicrobials

    Holiday Inn London - Kensington
    22nd March 2017
    London, United Kingdom

    VENUE

    Copthorne Tara Hotel

    Scarsdale Place, Kensington, London, United Kingdom

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    An Interview with Deborah O’Neil, Chief Executive Officer, Novabiotics Ltd

    Download

    Soligenix, Inc. Literature

    Download

    An Interview with Joe Sliman, Chief Medical Officer, Synthetic Biologics, Inc.

    Download

    Attendee List Superbugs 2017

    Download

    An Interview with Martin Everett, Chief Scientific Officer, Antabio

    Download

    New Interview Out with Danestat Consulting in the Run-up to Superbugs 2017

    Download

    An Interview with the John Innes Centre Ahead of Superbugs & Superdrugs 2017

    Download

    Invitation Letter

    Download

    Sponsors and Exhibitors


    MSD

    Sponsors and Exhibitors
    http://www.msd.com/

    For 125 years, MSD has been a global health care leader working to help the world be well. MSD is a tradename of Merck & Co., Inc., Kenilworth, N.J., USA. Through our prescription medicines, vaccines, biologic therapies, and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.msd.com


    Soligenix, Inc.

    Sponsors and Exhibitors
    http://www.soligenix.com

    Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is unmet medical need, including: 1) a therapeutics segment directed at cutaneous T-cell lymphoma and oral mucositis; and 2) a biodefense segment directed at ricin exposure, acute radiation syndrome and antibiotic resistant infectious disease.


    Synthetic Biologics

    Sponsors and Exhibitors
    http://www.syntheticbiologics.com

    Synthetic Biologics (NYSE MKT: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. Our lead programs poised for Phase III development include a beta-lactamase designed to protect the gut microbiome from residual intravenous antibiotics and a reformulation of lovastatin-lactone designed to reduce methane production in the gut.

    Media Partners


    Global Biodefense

    Official Media Partner
    http://www.globalbiodefense.com/

    Global Biodefense publishes the latest news on vaccine and therapeutics countermeasure development, biosurveillance and detection technologies, food safety and biosecurity, and CBRN incident preparedness and response. Visit our website to access daily news updates, organization profiles, conference listings, and the latest in funding opportunities for advancing biodefense technology.


    Rapid Microbiology.com

    Official Media Partner
    http://www.rapidmicrobiology.com

    rapidmicrobiology.com - keep up-to-date with all the latest products for your pharmaceutical microbiology laboratory, subscribe to the rapidmicrobiology.com newsletter http://www.rapidmicrobiology.com/Newsletter.php

    Media Partners


    Int. J. of Bioinformatics Research and Applications

    Official Publication
    http://www.inderscience.com/ijbra

    Bioinformatics is an interdisciplinary research field that combines biology, computer science, mathematics and statistics into a broad-based field that will have profound impacts on all fields of biology. The emphasis of IJBRA is on basic bioinformatics research methods, tool development, performance evaluation and their applications in biology. IJBRA addresses the most innovative developments, research issues and solutions in bioinformatics and computational biology and their applications.


    International Journal of Risk Assessment and Management

    Official Publication
    http://www.inderscience.com/ijram

    IJRAM is an interdisciplinary and refereed journal that provides cross learning between: • Different business and economics, as well as scientific and technological, disciplines • Energy industries, environmental and ecological systems • Safety, public health and medical services • Software services, reliability and safety


    Int. J. of Biotechnology

    Official Publication
    http://www.inderscience.com/ijbt

    IJBT provides an international forum and refereed authoritative source of information in the field of Biotechnology and Biotechnics, with emphasis on management and economics, as well as the political and social issues. It aims to disseminate knowledge, provide a learned reference in the field, and establish channels of communication between academic and research experts, policy makers and executives in industry, commerce and investment institutions.


    International Journal of Food Safety, Nutrition and Public Health

    Official Publication
    http://www.inderscience.com/jhome.php?jcode=ijfsnph

    IJFSNPH contributes to the improvement of public health through quality research and a better understanding of the science involved in food safety, nutrition and dietetics, food studies, food and restaurant management. To promote better health for all, this initiative aims to broaden the context of public health and health equity, integrate the study of these various disciplines, and foster knowledge transfer on key issues regarding the pivotal role of food safety, nutrition and health equity in influencing health outcomes.

    Media Partners


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Labiotech.eu

    Supporters
    http://labiotech.eu

    Labiotech.eu is the leading digital media covering the European Biotech industry. It is used by over 55000 people monthly to keep a watch on the business and innovations of biotechnologies.


    Pharmavision

    Supporters
    http://www.pharmavision.co.uk

    PharmaVision offers a consultancy service providing independent pharmaceutical thematic research to the healthcare industry, the investment community and competitive intelligence specialists. We perform due diligence research and provide expert commentary in healthcare. Our reports combine scientific analysis in drug delivery, R&D technologies and pharmaceutical products including patient modelling, product/technology forecasts and market trends evaluation.


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    CanBiotech

    Supporters
    http://www.canbiotech.com

    CanBiotech - A Portal and B2B Outsourcing Marketplace for the Biotech and Pharmaceutical Industry. The Marketplace features the Outsourcing Services Showcase; the Portal features our biopharmaceutical and venture capital directories and databases. Publications include the BioMedical Outsourcing Report and the Bio Outsourcing Asia© Publication.


    Swiss Biotech Association

    Supporters
    http://www.swissbiotech.org/

    The Swiss Biotech Association (SBA) is the national industry association for biotechnology, including pharmaceuticals, diagnostics, agriculture, food, cosmetics, environmental biotechnology, and specialty chemicals. Members are companies active in modern biotechnology, such as R&D, Production, Marketing and Sales, Finance, Services and Consulting. SBA provides a networking platform for Life Science clusters, academic and federal institutions the like. Founded in March 1998, the Association grows steadily.


    GBI

    Supporters
    http://www.gbihealth.com/

    GBI is an information, applications, and services company focused on the healthcare industry. Leveraging data from across the healthcare value chain, GBI creates web and mobile applications that enable individuals and organizations to make better decisions and communicate more effectively.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    KBI Biopharma

    Supporters
    http://www.kbibiopharma.com

    KBI also provides services from its industry-leading Particle Characterization Core Facility, including a full range of particle detection methods and data analysis utilizing MFI, Archimedes, NTA, Helix, Morphologi G3-ID, and Viscosizer instruments.


    Absave

    Supporters
    http://www.absave.com

    Absave.com is the leading savings website for Antibodies and Immunological Products. Search our extensive database of Antibodies, Kits, Proteins & Peptides, Reagents, etc. to find the best savings!


    BioPharm Insight

    Supporters
    http://www.biopharminsight.com

    BioPharm Insight is your definitive guide to the global life sciences community. Subscribers take action on forward-looking intelligence uncovered by an independent team of investigative journalists, and make strategic business decisions using the most comprehensive and powerful real-time database of market analytics and key contacts. Featuring an intuitive online interface and exclusive Active IntelT relational content technology, BioPharm Insight provides an unrivaled capability to segment and analyze the industry with detailed and searchable profiles.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique Partnering Search service and its global network of industry experts to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing, and its sister service Medical Device Licensing (www.medicaldevicelicensingcom) are actively utilized by over 200,000 industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.


    Farmavita

    Supporters
    http://www.farmavita.net/

    Farmavita Net is professional community and network of pharmaceutical licensing and business development executives, innovators and researchers
    Farmavita.Net is the pharmaceutical licensing, technology transfer and regulatory affairs network. We are managing the marketplace of offers and demand for pharmaceutical Dossiers, know-how and technologies. Members of Farmavita.Net network usually find a number of attractive solutions for business development, alliances, joint ventures, co-development and co-marketing of pharmaceutical products. Farmavita.Net is not just a pure Internet portal. We manage a number of regional associates. We are connecting the dynamic network of few hundreds members / pharmaceutical companies interested in license-in and license-out opportunities.


    Contract Biotechnology

    Supporters
    http://www.contract-biotechnology.com

    Contract-Biotechnology.com is a web-based platform for laboratory outsourcing solutions. We are an online R&D matching tool that connects Scientifics and organizations involved in discovery, development and delivery of new healthcare products with service and products providers worldwide. Life science information technology is undergoing a revolution. Part of that revolution involves new, unexplored business models, open innovation, open data and collaboration. If you have a project or idea that you would like to propose, develop or run, we can help. A New Collaboration Network Model for Discovery Research and Development • Effective Platform: the 95% • 5.000 registered users // > 15.000 Newsletter subscribers • Geographical background: 45,5% Europe / 37,5% North America / 16,5% Asia / 0,5% ROW • Professional background: Outsourcing Manager, Project Manager, CEO, Business Developer, CSO, Account Manager, Sales & Marketing People, Scientists, R&D. For further information, please visit our website www.contract-biotechnology.com


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today is one of the most cited review journals in the field of drug discovery, with an impact factor of 6.422.
    Drug Discovery Today will benefit your research by helping to keep you up-to-date with all of the fast-moving and emerging topics in drug discovery. Each issue is packed full of the latest research news, peer-reviewed articles and comment and opinion from leading research scientists.


    PMR

    Supporters
    http://www.pmrcorporate.com

    PMR (www.pmrcorporate.com) is a British-American company providing market information, advice and services to international businesses interested in Central and Eastern European countries as well as other emerging markets. PMR's key areas of operation include business publications (through PMR Publications), consultancy (through PMR Consulting) and market research (through PMR Research ). Being present on the market since 1995, offering high international standards in projects and publications, as well as providing one of the most frequently visited and top-ranked websites, PMR is one of the largest companies of its type in the region.


    Inderscience Publishers

    Supporters
    http://www.inderscience.com

    Inderscience is a dynamic, leading, independent journal publisher. The company disseminates the latest research across the broad fields of science, engineering and technology; management, public and business administration; environment, ecological economics and sustainable development; computing, ICT and internet/web services, and related areas. Inderscience offers over 35 years' experience in publishing and has succeeded in building a substantial collection approaching 400 high-quality peer-reviewed international research journals in both online and print formats. We offer a variety of ways to keep up-to-date with the latest published leading-edge research while our online collection represents a fully-searchable digital archive of around 60,000 articles.


    Labsave

    Supporters
    http://www.labsave.com

    Labsave is the leading savings website for Laboratory Equipment and Lab Supplies. We work closely with the top suppliers in the world to bring you the best products at the most competitive prices. We are constantly striving to secure the biggest and most exclusive offers that you won’t find anywhere else! http://www.labsave.com/


    SelectScience

    Supporters
    http://www.selectscience.net/register?utm_source=Media-Partner&utm_medium=Website&utm_campaign=SMI

    SelectScience is an independent, online information resource for the worldwide scientific community, and the home of trusted information for laboratory scientists. Discover the latest drug discovery and development technologies, products and techniques with product reviews, videos, application notes and news articles. Become a member for free today.


    Labhoo

    Supporters
    http://www.labhoo.com



    International Pharmaceutical Industry

    Supporters
    http://www.ipimediaworld.com

    IPI gives you an insight into all areas of Biopharm, Medical, Pharmaceutical and Healthcare. IPI provides a proven supportive means of communication to the Pharmaceutical, Bio Pharmaceutical, Nutraceutical and Medical Devices industry, incorporating the latest in research and technology innovations, regulatory guidelines, marketing and communication strategies.


    Biosave

    Supporters
    http://www.Biosave.com

    Biosave.com brings together the best Life Science promotions, product releases, featured products, publications, videos and events from 100’s of leading Life Science suppliers. Updated 24 hours a day, Biosave is constantly uploading special promotions and exciting product news that you won’t find anywhere else. Our goal is to provide our users with the most exclusive product information to help reach that all important purchasing decision.


    Conference-Service.com

    Supporters
    http://www.conference-service.com/

    COMS is a web application for managing delegate registration, payment, paper submission and paper review. Written in Perl and C, with a MySQL database at the back end, it is a comprehensive and powerful, yet easy to use solution for online conference management.


    Copybook - Pharmaceutical

    Supporters
    http://www.copybook.com/pharmaceutical

    Copybook is a global business network with many pharmaceutical events, exhibitions and seminars. We encourage business-to-business transactions and work tirelessly to gain our customers new business contracts worldwide. You can add events, companies and associations for free. When you are a member, you can add your company to the events listed in order to encourage other visitors to arrange meetings and appointments at those events to facilitate new business contracts. Want to see how we can increase your business network and transactions? SIGN UP FOR FREE today! Copybook – Your Global Business Network


    British Pharmacological Society

    Supporters
    http://www.bps.ac.uk

    The British Pharmacological Society (BPS) is the primary UK learned society concerned with research into drugs and the way they work. Our members work in academia, industry, regulatory agencies and the health services, and many are medically qualified. The Society covers the whole spectrum of pharmacology, including laboratory, clinical, and toxicological aspects. Clinical pharmacology is the medical speciality dedicated to promoting safe and effective use of medicines for patient benefit. Clinical pharmacologists work as consultants in the NHS and many hold prominent positions in UK Universities.


    PharmaVOICE

    Supporters
    http://www.pharmavoice.com

    PharmaVOICE magazine, and its supporting VIEW publications, provide commentary about the challenges and trends impacting the life-sciences industry, covering a range of issues from molecule through market. PharmaVOICE's more than 41,000 U.S.-based subscribers are also kept abreast of the latest trends through additional media resources, including WebSeminars, Podcasts, Videocasts, and White Papers.


    Bentham Science

    Supporters
    http://www.benthamscience.com/

    Bentham Science Publishers is a major STM journal publisher of 116 titles and 200 plus open access journals and print/online book series (Bentham eBooks). Bentham Science answers the information needs of the pharmaceutical and biomedical research community. Leading journals include Current Drug Metabolism (Impact Factor 5.113) and Current Medicinal Chemistry (Impact Factor 4.859): FREE online journals and information: www.benthamscience.com


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Drug Target Review

    Supporters
    http://www.drugtargetreview.com

    Drug Target Review’s quarterly magazine, website and annual events program provides high quality content with peer-written articles that are submitted exclusively by the world’s most respected scientists in their field. This attracts a committed base of readers, users and delegates made up of senior decision-makers from the life science and drug discovery industries at the top pharmaceutical companies, as well as academics and scientists from the top research institutes across the globe.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com


    Technology Networks

    Supporters
    http://www.technologynetworks.com

    Founded in 2000, Technology Networks is established as the leading news provider for life science and drug discovery professionals. In addition, we provide unique content including webcasts, videos, application notes and posters from recent conferences. Our portfolio now includes around 30 focussed scientific communities, all of which are accessible free of charge within TechnologyNetworks.com

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.